EDGAR·FLOW

Senti Biosciences Holdings, Inc. — Form SCHEDULE 13D/A

Filed November 18, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D/A — Neutral significance 28/100
What the filing says
Bayer Healthcare LLC filed an amended Schedule 13D/A on 2026-11-18 regarding beneficial ownership in Senti Biosciences Holdings, Inc. The filing does not disclose specific share counts, ownership percentages, transaction amounts, or details of what changed from the prior 13D filing. Without access to the actual amendment content, the material facts cannot be determined.
Why this rating

Schedule 13D amendments are routine disclosure updates. Without concrete data on share count, ownership %, or transaction size relative to Senti's $53.2M market cap, cannot assess materiality. Standard regulatory filing.

View original filing on SEC.gov ↗ SNTI · stock on Yahoo Finance ↗

See more from November 18, 2026.

EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.